IE45443B1 - Improvements in or relating to immunolgical agents - Google Patents

Improvements in or relating to immunolgical agents

Info

Publication number: IE45443B1
Authority: IE; Ireland
Prior art keywords: drug; target; antigens; target antigens; insoluble
Prior art date: 1976-06-29

Application number

IE1313/77A

Other languages

English (en)

Other versions

IE45443L (en

Original Assignee

Inst Nat Sante Rech Med

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-06-29

Filing date

1977-06-27

Publication date

1982-08-25

1977-06-27 Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med

1977-12-29 Publication of IE45443L publication Critical patent/IE45443L/xx

1982-08-25 Publication of IE45443B1 publication Critical patent/IE45443B1/en

Links

239000000427 antigen Substances 0.000 claims abstract description 100
102000036639 antigens Human genes 0.000 claims abstract description 60
108091007433 antigens Proteins 0.000 claims abstract description 60
239000003814 drug Substances 0.000 claims abstract description 51
239000000677 immunologic agent Substances 0.000 claims abstract description 13
230000001843 schistosomicidal effect Effects 0.000 claims abstract description 13
229940124541 immunological agent Drugs 0.000 claims abstract description 12
229940079593 drug Drugs 0.000 claims description 46
238000000034 method Methods 0.000 claims description 26
241000242678 Schistosoma Species 0.000 claims description 16
239000003446 ligand Substances 0.000 claims description 14
229950008495 amphotalide Drugs 0.000 claims description 9
GIIGAFADHXYOPM-UHFFFAOYSA-N amphotalide Chemical compound C1=CC(N)=CC=C1OCCCCCN1C(=O)C2=CC=CC=C2C1=O GIIGAFADHXYOPM-UHFFFAOYSA-N 0.000 claims description 8
229960005130 niridazole Drugs 0.000 claims description 8
239000000243 solution Substances 0.000 claims description 8
RDXLYGJSWZYTFJ-UHFFFAOYSA-N Niridazole Chemical compound S1C([N+](=O)[O-])=CN=C1N1C(=O)NCC1 RDXLYGJSWZYTFJ-UHFFFAOYSA-N 0.000 claims description 7
HTKFORQRBXIQHD-UHFFFAOYSA-N allylthiourea Chemical compound NC(=S)NCC=C HTKFORQRBXIQHD-UHFFFAOYSA-N 0.000 claims description 7
MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 claims description 6
AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 claims description 6
229960002694 emetine Drugs 0.000 claims description 6
AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 claims description 6
AOGOCZMBIYQOFE-UHFFFAOYSA-B hexasodium;2-[1,2-dicarboxylato-2-[(4,5-dicarboxylato-1,3,2-dithiastibolan-2-yl)sulfanyl]ethyl]sulfanyl-1,3,2-dithiastibolane-4,5-dicarboxylate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].S1C(C([O-])=O)C(C([O-])=O)S[Sb]1SC(C([O-])=O)C(C(=O)[O-])S[Sb]1SC(C([O-])=O)C(C([O-])=O)S1 AOGOCZMBIYQOFE-UHFFFAOYSA-B 0.000 claims description 6
AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 claims description 5
239000012047 saturated solution Substances 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 3
239000007853 buffer solution Substances 0.000 claims description 2
IIQJBVZYLIIMND-UHFFFAOYSA-J potassium;antimony(3+);2,3-dihydroxybutanedioate Chemical compound [K+].[Sb+3].[O-]C(=O)C(O)C(O)C([O-])=O.[O-]C(=O)C(O)C(O)C([O-])=O IIQJBVZYLIIMND-UHFFFAOYSA-J 0.000 claims description 2
238000011210 chromatographic step Methods 0.000 claims 1
244000045947 parasite Species 0.000 abstract description 9
238000000926 separation method Methods 0.000 abstract description 2
230000000347 anti-schistosomal effect Effects 0.000 abstract 2
241000699670 Mus sp. Species 0.000 description 18
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
210000002966 serum Anatomy 0.000 description 16
239000000499 gel Substances 0.000 description 11
241000283973 Oryctolagus cuniculus Species 0.000 description 10
229920002684 Sepharose Polymers 0.000 description 10
238000000760 immunoelectrophoresis Methods 0.000 description 9
201000004409 schistosomiasis Diseases 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
241000700159 Rattus Species 0.000 description 8
241000242680 Schistosoma mansoni Species 0.000 description 7
230000002255 enzymatic effect Effects 0.000 description 7
238000002649 immunization Methods 0.000 description 7
206010061217 Infestation Diseases 0.000 description 6
239000000725 suspension Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241000699800 Cricetinae Species 0.000 description 5
238000002512 chemotherapy Methods 0.000 description 5
230000002440 hepatic effect Effects 0.000 description 5
230000010412 perfusion Effects 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
210000004201 immune sera Anatomy 0.000 description 4
229940042743 immune sera Drugs 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
230000004807 localization Effects 0.000 description 4
238000001042 affinity chromatography Methods 0.000 description 3
229940026189 antimony potassium tartrate Drugs 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
150000001718 carbodiimides Chemical class 0.000 description 3
210000004534 cecum Anatomy 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
WBTCZEPSIIFINA-MSFWTACDSA-J dipotassium;antimony(3+);(2r,3r)-2,3-dioxidobutanedioate;trihydrate Chemical compound O.O.O.[K+].[K+].[Sb+3].[Sb+3].[O-]C(=O)[C@H]([O-])[C@@H]([O-])C([O-])=O.[O-]C(=O)[C@H]([O-])[C@@H]([O-])C([O-])=O WBTCZEPSIIFINA-MSFWTACDSA-J 0.000 description 3
201000010099 disease Diseases 0.000 description 3
230000000984 immunochemical effect Effects 0.000 description 3
230000003071 parasitic effect Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
229920006051 Capron® Polymers 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
102000013460 Malate Dehydrogenase Human genes 0.000 description 2
108010026217 Malate Dehydrogenase Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000237852 Mollusca Species 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
229910052787 antimony Inorganic materials 0.000 description 2
WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
235000013601 eggs Nutrition 0.000 description 2
JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
239000012678 infectious agent Substances 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
238000000424 optical density measurement Methods 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000001376 precipitating effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
150000003141 primary amines Chemical group 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
238000012546 transfer Methods 0.000 description 2
238000005303 weighing Methods 0.000 description 2
HUEYSSLYFJVUIS-MRFSYGAJSA-N (2s,3r,11bs)-2-[[(1r)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizine;hydron;chloride Chemical compound Cl.N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC HUEYSSLYFJVUIS-MRFSYGAJSA-N 0.000 description 1
SGNXVBOIDPPRJJ-PSASIEDQSA-N 1-[(1r,6r)-9-azabicyclo[4.2.1]non-4-en-5-yl]ethanone Chemical compound CC(=O)C1=CCC[C@@H]2CC[C@H]1N2 SGNXVBOIDPPRJJ-PSASIEDQSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010031025 Alanine Dehydrogenase Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
108090000863 Carboxylic Ester Hydrolases Proteins 0.000 description 1
102000004308 Carboxylic Ester Hydrolases Human genes 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000035415 Reinfection Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000002009 allergenic effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003948 anatoxin Substances 0.000 description 1
229960002319 barbital Drugs 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000012505 colouration Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
229960001923 emetine hydrochloride Drugs 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
229960003699 evans blue Drugs 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000013905 glycine and its sodium salt Nutrition 0.000 description 1
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000011017 operating method Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Immunology (AREA)
Tropical Medicine & Parasitology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IE1313/77A 1976-06-29 1977-06-27 Improvements in or relating to immunolgical agents IE45443B1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR7620687A FR2356428A1 (fr)	1976-06-29	1976-06-29	Procede de preparation d'un agent immunologique antiparasitaire, produit obtenu et son application

Publications (2)

Publication Number	Publication Date
IE45443L IE45443L (en)	1977-12-29
IE45443B1 true IE45443B1 (en)	1982-08-25

Family

ID=9175335

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IE1313/77A IE45443B1 (en)	1976-06-29	1977-06-27	Improvements in or relating to immunolgical agents

Country Status (10)

Country	Link
JP (1)	JPS5362814A (fr)
BE (1)	BE855898A (fr)
CH (1)	CH623231A5 (fr)
DE (1)	DE2728802C2 (fr)
DK (1)	DK285777A (fr)
FR (1)	FR2356428A1 (fr)
GB (1)	GB1582294A (fr)
IE (1)	IE45443B1 (fr)
NL (1)	NL7707174A (fr)
SE (1)	SE7707311L (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4158049A (en) *	1976-09-27	1979-06-12	Edna Mcconnell Clark Foundation	Antigen fraction of Schistosoma mansoni eggs suitable for testing for schistosomiasis
US4493825A (en) *	1982-10-05	1985-01-15	Iowa State University Research Foundation	Purified and antigenically selective vaccines for domestic animals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2420706C3 (de) *	1974-04-29	1979-11-22	Behringwerke Ag, 3550 Marburg	Verfahren zum Herstellen von spezifischen Antigenen aus Schistosomen und jene enthaltendes Mittel

1976
- 1976-06-29 FR FR7620687A patent/FR2356428A1/fr not_active Withdrawn
1977
- 1977-06-20 CH CH753277A patent/CH623231A5/fr not_active IP Right Cessation
- 1977-06-21 BE BE2056013A patent/BE855898A/fr unknown
- 1977-06-23 SE SE7707311A patent/SE7707311L/ not_active Application Discontinuation
- 1977-06-27 DE DE2728802A patent/DE2728802C2/de not_active Expired
- 1977-06-27 IE IE1313/77A patent/IE45443B1/en unknown
- 1977-06-27 DK DK285777A patent/DK285777A/da not_active Application Discontinuation
- 1977-06-27 GB GB26775/77A patent/GB1582294A/en not_active Expired
- 1977-06-28 NL NL7707174A patent/NL7707174A/xx not_active Application Discontinuation
- 1977-06-29 JP JP7769877A patent/JPS5362814A/ja active Pending

Also Published As

Publication number	Publication date
DE2728802A1 (de)	1978-01-05
FR2356428A1 (fr)	1978-01-27
NL7707174A (nl)	1978-01-02
GB1582294A (en)	1981-01-07
CH623231A5 (en)	1981-05-29
BE855898A (fr)	1977-10-17
IE45443L (en)	1977-12-29
DE2728802C2 (de)	1982-04-22
DK285777A (da)	1977-12-30
JPS5362814A (en)	1978-06-05
SE7707311L (sv)	1977-12-30

Publication	Publication Date	Title
McKearn	1974	Anti-idiotypic antibody in rat transplantation immunity.
Notkins et al.	1966	Elevated γ-globulin and increased antibody production in mice infected with lactic dehydrogenase virus
Wick et al.	1973	Antigenic surface determinants of chicken lymphoid cells. I. Serologic properties of anti-bursa and anti-thymus sera
Neumann et al.	1992	In vivo deposition of myosin-specific autoantibodies in the hearts of mice with experimental autoimmune myocarditis
Chapman et al.	1979	IgG1 hypergammaglobulinaemia in chronic parasitic infections in mice: magnitude of the response in mice infected with various parasites
Payares et al.	1985	Antigenicity and immunogenicity of the tegumental outer membrane of adult Schistosoma mansoni
Ramalho‐Pinto et al.	1979	Murine Schistosomiasis mansoni: anti‐schistosomula antibodies and the IgG subclasses involved in the complement‐and eosinophilmediated killing of schistosomula in vitro
Van Rooijen	1972	Antigens in the spleen: The non-specificity of the follicles in the process of antigen trapping and the role of antibody
Holland et al.	1965	Haemagglutinating, precipitating and lymphocyte-stimulating factors of phytohaemagglutinin
Collins et al.	1981	Lack of evidence for a role of renal tubular antigen in human membranous glomerulonephritis
IE45443B1 (en)	1982-08-25	Improvements in or relating to immunolgical agents
Julius et al.	1977	Recognition of a naturally occurring idiotype by autologous T cells
Bernard et al.	1975	Inhibition by serum of encephalitogenic activity of myelin basic protein: nature of the serum factor responsible
Wang et al.	1967	Immune responses of mice to iodoacetate-treated Ehrlich ascites tumour cells
Mazza et al.	1990	Antibody isotype responses to the Schistosoma mansoni schistosomulum in the CBA/N mouse induced by different stages of the parasite life cycle
Sato et al.	1988	Studies on the induction of tolerance to alloantigens. III. Induction of antibodies directed against alloantigen-specific delayed-type hypersensitivity T cells by a single injection of allogeneic lymphocytes via portal venous route.
James et al.	1976	Antitumor antibodies and immunoglobulin class and subclass levels in Corynebacterium parvum-treated mice
US4178365A (en)	1979-12-11	Method of preparing an antiparasitic immunological agent, the product obtained, and its application
Berger et al.	1969	The effect of chlorphenesin on the immune response
Springer et al.	1982	Human blood groups M-, N-, T-, and Tn-specific substances in lipidic extracts of line 10 hepatocarcinoma of Strain 2 guinea pigs
Braley-Mullen et al.	1975	Differential susceptibility of strain 2 and strain 13 guinea pigs to induction of experimental autoimmune thyroiditis
Calderon et al.	1987	Circulating antigens and antibodies in human and mouse dermatophytosis: use of monoclonal antibody reactive to phosphorylcholine-like epitopes
Phillips et al.	1978	The cellular and humoral immune response to Schistosoma mansoni infections in inbred rats: V. Prerequisite mechanisms for the development of optimal protective immunity
Byfield et al.	1976	Murine neuroblastoma cured in vivo by an antibody-dependent cellular cytotoxicity reaction
Radzichovskaja	1968	Agglutinating antibodies in the sera of chickens with regressing Rous sarcomas